Literature DB >> 32998821

A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory.

Enzo Bonora1, Salvatore Cataudella2, Giulio Marchesini3, Roberto Miccoli3, Olga Vaccaro3, Gian Paolo Fadini3, Nello Martini4, Elisa Rossi2.   

Abstract

BACKGROUNDS AND AIMS: To investigate relevant indicators of quality of care in a large population-based sample of people with diabetes representative of clinical practice in Italy in 2018. METHODS AND
RESULTS: We analyzed data from 11,300,750 subjects. All administrative healthcare claims collected in 2018 were scrutinized to identify subjects with diabetes and investigate several indicators of quality of care. Subjects with diabetes were identified by anti-hyperglycemic drug prescriptions, disease-specific co-payment exemption and hospital discharge codes. Indicators of quality of care pertained to monitoring (HbA1c, creatinine, lipid profile, microalbuminuria, eye examination, ECG, ultrasonography of carotid and lower limb arteries) and diabetes treatment (anti-hyperglycemic agents in subjects with cardiovascular disease, CVD). Subjects attending and nonattending Diabetes Clinics were compared. We identified 697,208 individuals with diabetes. HbA1c was assessed at least once in the year in 62.7%, creatinine in 62.3%, total cholesterol in 59.6%, microalbuminuria in 34.3%. Frequency of eye examination was 8.2%, ECG 23.5%, carotid ultrasonography 14.3%, lower limb ultrasonography 7.6%. Among anti-hyperglycemic drugs, SGLT-2 inhibitors were prescribed to ~5% and GLP-1 receptor agonists to ~5% although the proportion of subjects with CVD was ~45%. Subjects attending Diabetes Clinics had higher figures for all these monitoring and treatment indicators.
CONCLUSIONS: The implementation of national and international guidelines regarding disease monitoring and treatment is far from being satisfactory, especially among subjects nonattending Diabetes Clinics. Further efforts and investments are needed for better disseminating guidelines, more efficaciously engaging healthcare professionals and more strongly empowering the healthcare system to improve diabetes care.
Copyright © 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adherence; Anti-hyperglycemic agents; Diabetes mellitus; Monitoring; Quality of care

Mesh:

Substances:

Year:  2020        PMID: 32998821     DOI: 10.1016/j.numecd.2020.08.018

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  6 in total

1.  Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis.

Authors:  Santo Colosimo; Federico Ravaioli; Maria L Petroni; Lucia Brodosi; Francesca Marchignoli; Francesca A Barbanti; Anna S Sasdelli; Giulio Marchesini; Loris Pironi
Journal:  Liver Int       Date:  2021-02-10       Impact factor: 5.828

Review 2.  Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors.

Authors:  Gian Paolo Fadini; Stefano Del Prato; Angelo Avogaro; Anna Solini
Journal:  Diabetes Obes Metab       Date:  2021-11-24       Impact factor: 6.408

3.  Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis.

Authors:  B M Bonora; A Avogaro; G P Fadini
Journal:  J Endocrinol Invest       Date:  2021-01-29       Impact factor: 4.256

4.  Ambulatory Healthcare Use Profiles of Patients With Diabetes and Their Association With Quality of Care: A Cross-Sectional Study.

Authors:  Julien Dupraz; Emilie Zuercher; Patrick Taffé; Isabelle Peytremann-Bridevaux
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-13       Impact factor: 6.055

5.  SARS-CoV-2 and COVID-19 in diabetes mellitus. Population-based study on ascertained infections, hospital admissions and mortality in an Italian region with ∼5 million inhabitants and ∼250,000 diabetic people.

Authors:  Enzo Bonora; Ugo Fedeli; Elena Schievano; Maddalena Trombetta; Mario Saia; Giovanna Scroccaro; Evelina Tacconelli; Giacomo Zoppini
Journal:  Nutr Metab Cardiovasc Dis       Date:  2021-06-29       Impact factor: 4.222

6.  Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.

Authors:  Mario Luca Morieri; Angelo Avogaro; Gian Paolo Fadini
Journal:  Cardiovasc Diabetol       Date:  2020-11-10       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.